Vitamin K2

Vitamin K2 is a fat-soluble cofactor for a single enzyme — γ-glutamyl carboxylase (GGCX) — which activates a small family of vitamin-K-dependent proteins (VKDPs) that control where calcium goes in the body. That sounds narrow, and mechanistically it is, but the downstream effect is what makes K2 the default cardiovascular and skeletal insurance under D3, AAS cycles, and high-calcium diets: activated VKDPs route calcium into bone and out of arterial walls.

γ-Carboxylation of Matrix Gla Protein (MGP) — the Arterial Calcium Switch#

Every mole of K2 in circulation is ultimately feeding the vitamin K cycle, where GGCX uses reduced K2 (hydroquinone form) to post-translationally carboxylate glutamate residues on VKDPs. VKORC1 then recycles the oxidized K2 back to its active form — this is the same enzyme warfarin blocks, which is why K2 intake has to stay stable if you're anticoagulated.

The most physique- and longevity-relevant substrate is matrix Gla protein (MGP). Only the carboxylated form of MGP (cMGP) binds calcium in the arterial wall and prevents its deposition; uncarboxylated MGP (ucMGP) is biologically inert and tracks directly with vascular calcium burden. MK-7 drives this carboxylation meaningfully better than K1 at equimolar doses:

"MK-7 supplementation resulted in more effective carboxylation of both osteocalcin and matrix Gla-protein than did vitamin K1, shown by significant reduction in circulating uncarboxylated forms." — Schurgers LJ et al., Blood, 2007

Practically, this is the mechanism behind the "K2 keeps calcium out of your arteries" argument — and it's why running high-dose D3 without K2 is the exact scenario users want to avoid. D3 upregulates intestinal calcium absorption; without adequate cMGP, more of that calcium is available to partition into vascular smooth muscle and the aortic wall. In a 3-year trial, MK-7 at 180 µg/day reduced age-related progression of carotid-femoral pulse wave velocity — a direct, quantitative measure of arterial stiffness — versus placebo (Knapen 2015).

Osteocalcin Activation and Bone Mineralization#

The second major VKDP is osteocalcin (OC), secreted by osteoblasts. Carboxylated osteocalcin (cOC) binds calcium into the hydroxyapatite matrix of bone; uncarboxylated osteocalcin (ucOC) doesn't. The ucOC:cOC ratio is the most responsive serum biomarker to K2 dosing and drops dose-dependently with MK-7 at intakes as low as 90 µg/day.

"This study shows that MK-7 supplementation (180 µg/day) significantly improved bone mineral content and bone strength at the femoral neck after 3 years." — Knapen MHJ et al., Osteoporos Int., 2013

For physique-focused users, this matters in a few specific scenarios: anyone running aromatase inhibitors long enough to suppress estradiol below the bone-turnover threshold, users with stress-fracture history, and older lifters stacking D3 for immune or T-support. K2 is also why the Japanese 45 mg/day MK-4 protocol has hard fracture-endpoint RCT data — it drives cOC synthesis hard enough to shift bone-quality outcomes, not just BMD scores.

The MK-4 vs MK-7 Pharmacokinetic Split#

The two community-relevant forms act on the same GGCX mechanism but have radically different pharmacokinetics, which is why they're used differently:

"MK-7 exhibited slow absorption, reaching maximum plasma concentration approximately 6 hours post dosing, with a long elimination half-life (~72 hours)." — Jadhav N et al., Biomed Res Int., 2023

MK-7's long tail is the reason once-daily dosing drives stable carboxylation of MGP and OC — the enzyme has continuous substrate. MK-4, with its short half-life, requires 3×/day dosing to maintain tissue exposure, which is why the osteoporosis protocol is split and why MK-4 at once-daily supplemental doses (5–15 mg) is doing less mechanistically than users assume. For the cardiovascular-partitioning use case, MK-7 is the form that matches the mechanism.

Endothelial and Epidemiological Signal#

Beyond MGP carboxylation, K2 has secondary vascular effects through inhibition of bone morphogenetic protein 2 (BMP-2) signalling in vascular smooth muscle — BMP-2 is the master driver of osteogenic transdifferentiation, where vascular smooth muscle cells start behaving like osteoblasts and laying down calcium phosphate in the arterial wall. K2 blunts this phenotype switch independently of the MGP pathway.

This is mechanistically consistent with the two large Dutch cohorts:

"High intake of dietary menaquinone was associated with a reduced risk of coronary heart disease mortality (RR 0.43; 95% CI 0.24–0.77) and severe aortic calcification." — Geleijnse JM et al., Journal of Nutrition, 2004

"Each 10-µg increase in menaquinone intake was associated with a 9% lower risk of CHD (hazard ratio 0.91, 95% CI 0.85–0.98)." — Gast GCM et al., Nutr Metab Cardiovasc Dis., 2009

Epidemiology is epidemiology — it doesn't prove causation — but the mechanistic chain (MK-7 → cMGP → reduced arterial calcification → reduced CHD) is one of the cleaner stories in the supplement space, and the dose-response holds across independent cohorts.

Practical Translation#

For the physique-focused user, K2's mechanism resolves to three concrete outcomes:

1. Cardiovascular partitioning on cycle or on D3. AAS cycles already pressure the calcification axis through LVH, arterial stiffening, and lipid shifts; K2 directly addresses the calcification component by keeping MGP activated. It does not fix hematocrit, LDL-P, or hypertension — don't mistake it for a cardio-protective silver bullet.
2. Bone density support under AI use, GnRH-agonist exposure, low-estrogen states, or simply age — via sustained cOC activation.
3. Directional insurance against soft-tissue calcification (kidney, valves, joints) in users running year-round high-dose D3, where ucMGP otherwise climbs.

K2 doesn't build muscle, burn fat, or shift the HPTA. It does one thing — carboxylate VKDPs — and that single mechanism is why it sits in the "run continuously" tier of the stack.

Common (most users)#

K2 is one of the cleanest supplements in the stack. In the 3-year Knapen MK-7 trial at 180 µg/day, adverse events didn't differ from placebo — and that's the longest controlled dataset we have.

• Mild GI upset (bloating, loose stool) — uncommon at standard doses. If it shows up, take with a larger fat-containing meal instead of on an empty stomach, or split MK-4 doses across the day.
• Transient headache — rare, usually at the first few days of a higher-dose MK-7 protocol (≥300 µg). Resolves on its own; drop to 100–200 µg if persistent.
• "Nothing happens" — the most common user complaint. K2 doesn't produce acute subjective effects. Its endpoints are ucMGP, ucOC, pulse wave velocity, and BMD measured over years, not a next-day pump or energy shift. Adjust expectations, not dose.

"MK-7 supplementation resulted in more effective carboxylation of both osteocalcin and matrix Gla-protein than did vitamin K1, shown by significant reduction in circulating uncarboxylated forms." — Schurgers et al., Blood (2007)

Uncommon (dose-dependent or individual)#

• GI discomfort or headache at high MK-7 doses (>360 µg/day) — back down to 180–200 µg. There's no meaningful evidence that pushing past 360 µg adds benefit for users who are already D3-replete.
• INR drift in users on warfarin who start, stop, or vary K2 dose — this is a dosing-stability problem, not a toxicity problem. See contraindications.
• No effect on lipids, hematocrit, or liver enzymes — K2 doesn't move these panels. If you're running it and your LDL or HCT is climbing on cycle, K2 isn't the lever; look at your AAS, orals, and omega-3/citrus bergamot stack.
• Cis-isomer MK-7 products "not working" — cheap bulk MK-7 is often a cis/trans mix, and the cis isomer is biologically inert. If ucOC isn't budging on a supposedly adequate dose, suspect the product before the protocol. Branded trans-only MK-7 (MenaQ7 and similar) is worth the price delta.

Rare but serious#

• Meaningful bleeding events in non-anticoagulated users — not reported at supplemental doses. K2 doesn't thin blood or thicken it at these ranges; it's a cofactor, not a driver.
• Allergic reaction to softgel excipients (soy lecithin, MCT carrier) — rare, not K2 itself. Switch to a clean-label or oil-free capsule.
• Hypercalcemia — not caused by K2. If calcium rises, the lever is almost always the D3 dose or an underlying parathyroid issue, not the K2. Pull D3, not K2.

Hard contraindications#

• Warfarin and other coumarin anticoagulants (acenocoumarol, phenprocoumon). K2 is the substrate of the enzyme warfarin inhibits. Starting or stopping K2 — or varying the dose — will shift INR and can cause either clotting or bleeding. If you're on warfarin, either don't supplement K2, or hold the dose rigidly constant and have INR re-titrated by whoever manages your anticoagulation. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are not affected — they don't work through the K cycle, and K2 is fine alongside them.
• Known hypersensitivity to menaquinones — obvious, exceedingly rare.

Gender-specific, pregnancy, and PCT considerations#

K2 does not touch the HPTA, aromatase, 5-AR, or any steroid pathway. No virilization risk, no suppression, no PCT implications. It is safe in pregnancy and lactation at supplemental doses — K-dependent carboxylation is a fetal and neonatal requirement, and injectable K1 is given routinely at birth. No cycling needed: run it continuously, at the same dose year-round, as the base of your D3 stack.